To demonstrate that the Insight Pro Device is safe and effective for use in detecting lymphatic and venous disorders.

6. Clinical Hypotheses

1. The Insight Pro device can detect a difference in extracellular fluid volume through bioimpedance and dielectric constant measurement.
2. The Insight Pro device can detect a difference in skin hardness or fibrositis through a durometer measurement.
3. The Insight Pro device is safe for use as assessed by adverse events.

Inclusion Criteria:

Test group -

• Males and females ≥ 18 years of age
• Willing to sign the informed consent and deemed capable of following the study protocol
• Subjects must have primary or secondary unilateral or bilateral upper or lower extremity edema
• At the time of initial evaluation, individuals must be at least 3 months post-surgery, chemotherapy and/or radiation treatment for cancer if applicable

Control group -

• Males and females ≥ 18 years of age
• Willing to sign the informed consent and deemed capable of following the study protocol
• Subjects must not have primary or secondary edema and self-describe general healthy

Exclusion Criteria:

• ● Inability or unwillingness to participate in all aspects of the study protocol and/or failure to provide informed consent

  • Patients with exam results that would prevent safe and effective use of the study device (cellulitis, open-wounds, healing-wounds, etc.)
  • Diagnosis of active or recurrent cancer (< 3 months since completion of chemotherapy, radiation therapy, or primary surgery for the cancer)
  • Patients with cardiac arrhythmia with pacemakers or other implanted electronic equipment
  • Patients must not have implanted metal hardware in the limbs
  • Patients undergoing external defibrillation
  • Diagnosis of Acute infection (in the last four weeks)
  • Diagnosis of acute thrombophlebitis (in last 2 months)
  • Diagnosis of pulmonary embolism or deep vein thrombosis within the previous 2 months
  • Diagnosis of congestive heart failure (uncontrolled)
  • Diagnosis of chronic kidney disease with acute renal failure
  • Women who are pregnant, planning a pregnancy or nursing at study entry
  • Participation in any clinical trial of an investigational substance or device during the past 30 days

(Test Group) - Up to 50 subjects will be enrolled with unilateral or bilateral edema in the upper or lower extremity.

(Control Group) Up to 50 patients will be enrolled from a healthy volunteer group as a control, with no edema.